| Literature DB >> 33844410 |
Tal Ben-Ami1, Udo Kontny2, Aurore Surun3, Ines B Brecht4, Ricardo López Almaraz5, Monica Dragomir6, Apostolos Pourtsidis7, Michela Casanova8, Brice Fresneau9,10, Gianni Bisogno11, Dominik T Schneider12, Yves Reguerre13, Ewa Bien14, Teresa Stachowicz-Stencel14, Gustaf Österlundh15, Marc Wygoda16, Geert O Janssens17,18, József Zsiros18, Nina Jehanno19, Herve J Brisse20, Lorenza Gandola21, Hans Christiansen22, Line Claude23, Andrea Ferrari8, Carlos Rodriguez-Galindo24, Daniel Orbach3.
Abstract
Nasopharyngeal carcinoma (NPC) is a rare pediatric tumor. Collaborative studies performed over the last decades showed improved results compared to historical data, but standardized guidelines for diagnosis and management of pediatric NPC are still unavailable. This study presents a European consensus guideline for the diagnosis and treatment of pediatric NPC developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Main recommendations include induction chemotherapy with cisplatin and 5-flurouracil, concomitant chemoradiotherapy in advanced disease, and to consider maintenance treatment with interferon beta (IFN-β) for selected high-risk patients. Dose adjustments of radiotherapy based on response to induction chemotherapy may decrease the rates of long-term treatment-related complications that affect most of the survivors.Entities:
Keywords: adolescent; children; nasopharyngeal carcinoma; radiotherapy; rare tumors; recommendations
Mesh：
Substances：
Year: 2021 PMID： 33844410 DOI： 10.1002/pbc.29018
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167